echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nature: Scientists find key to 'stopping' cancer cells - TRIM37 or cell division 'inverter'

    Nature: Scientists find key to 'stopping' cancer cells - TRIM37 or cell division 'inverter'

    • Last Update: 2020-09-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cells divide all the time in the body, and uncontrolled errors in the process can contribute to genetic errors and may continue to develop into cancer cells.
    since cancer cells were discovered more than 100 years ago, scientists have been trying to find ways to kill these "harmful" cells and cure cancer.
    , the top journal, Nature, published two high-quality articles on cancer treatment.
    this tweet, the editor-in-chief shared the first one - by Oxford University and John F. Kennedy. An article by scientists at Hopkins University, entitled Target TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer, kills certain human breast cancer cells by selectively attacking the core of the cell division mechanism, providing new inspiration for our search for drugs that destroy cancer cells without harming healthy cells.
    , one of the report's co-authors, John F. Kennedy, said: "It's a very important one. Dr Andrew Holland, associate professor of molecular biology and genetics at Hopkins University School of Medicine, said: "Some widely used anticancer drugs have killed rapidly dividing cells, but these drugs have obvious drawbacks and can damage healthy cells while killing cancer cells.
    " the key is how to destroy cancer cells while protecting healthy cells? Because mammalian cell division processes are similar, Holland's team has long tried to find breakthroughs in cell division mechanisms specific to cancer cells.
    is an important cytogenetic device in animal cells and the center of internal activity during cell division.
    although some cancer cells can proliferate without a central body, the researchers found that there are a range of human breast cancer cells (MCF-7) that rely heavily on the central body for cell division and survival.
    in the study, researchers found that centrally dependent breast cancer cells contained 17q23 breast cancer amplifier, an abnormal number of duplicate copies of 3-4-Mb found in about 9 percent of breast cancer cells.
    researchers screened TRIM37 from about 40 protein-coding genes in 17q23 amplifications, which have previously been reported to be associated with central body function, and knocking out this gene will lead to the accumulation of substances around the center of the center of the center of the center of the center of the center of the center of the center of the center of the center of the center of the center of the center of the non-central granulocytes (PCM) and the accelerated assembly of spindles.
    previous studies have shown that the protein kinase PLK4 is a target for blocking the growth of invasive breast cancer cells, and that PLK4 inhibitors can destroy the proteins that make up the central protein, leading to central failure.
    researchers added PPK4 inhibitors to normal trim37-level breast cancer cells grown in the lab and found that even if the center of the cancer cells were removed, they could still divide.
    if PLC4 inhibitors are added to breast cancer cells with high TRIM37 levels, most cells will stop growing or dying.
    suggests that the increase in TRIM37 expression is synthetic and lethal under the inhibition of PLC4.
    subsequent experiments also confirmed this and further demonstrated that the inhibitor selectivity of PLK4 (rather than other kinases) played a key role in over-expression of the synthetic lethal effects of TRIM37 cells.
    PLK4 inhibitor selective rather than other kinases are necessary to synthesize lethal killing of overexpressed TRIM37 cells In order to study how PLC4 inhibition triggers growth defects in MCF-7 cells, the researchers used a time-lapse microscope to track the growth of cancer cells using and not using PLC4 inhibitors.
    results show that, in the absence of the central body, TRIM37 is the negative regulatory factor of the substance around the central body, and the increase of TRIM37 expression affects the assembly of the spindle body, resulting in a sudden change in silk division.
    further analysis shows that TRIM37 over-expression inhibits the formation of non-central PCM cooktops, which have micro-tube nucleation capability and are necessary structures for the successful cell division of the lack of central bodies.
    The last model that expressed TRIM37's inhibitory PLC4 synthetic lethal effect in 17q23 amplified breast cancer cells, the researchers also found that TRIM37 overexpression increased the frequency of silk division errors by delaying the maturation of the central body and accelerating the separation of the central body as it entered the silky division.
    , by adding PPK4 inhibition to remove the central grain, whether or not the cancer cell has a central body or PCM, it will not be able to organize the pipes that help the DNA divide during cell division.
    overall, this study shows that inhibiting PLC4 or other regulatory factors associated with central replication and assembly is a promising treatment strategy for selective targeting of breast cancer or other tumors driven by 17q23 amplification.
    , researchers are looking for other, more stable drugs similar to PPK4 inhibitors and are trying to identify other human cancer cell lineages that are sensitive to these inhibitors.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.